prochlorperazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2274 58-38-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prochlorperazine mesylate
  • prochlorperazine
  • capazine
  • chlormeprazine
  • chlorperazine
  • meterazin
  • meterazine
  • proazine
  • prochlorpemazine
  • prochlorperazin
  • prochlorpromazine
  • prochlorperazine maleate
  • prochlorperazine edisylate
  • prochlorperazine dimaleate
  • prochlorperzine
A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
  • Molecular weight: 373.94
  • Formula: C20H24ClN3S
  • CLOGP: 4.58
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 9.72
  • ALOGS: -4.53
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
50 mg P
0.10 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.83 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 23, 1956 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 353.75 11.64 1549 49912 754542 52543063
Febrile neutropenia 320.78 11.64 448 51013 104488 53193117
Drug ineffective 270.69 11.64 236 51225 817009 52480596
Disease progression 257.71 11.64 398 51063 101522 53196083
Dehydration 217.82 11.64 493 50968 167917 53129688
Diarrhoea 198.68 11.64 1151 50310 624395 52673210
White blood cell count decreased 198.58 11.64 397 51064 124078 53173527
Vomiting 193.81 11.64 968 50493 496171 52801434
Plasma cell myeloma 156.02 11.64 211 51250 47663 53249942
Platelet count decreased 136.85 11.64 314 51147 107785 53189820
Fatigue 135.78 11.64 1181 50280 729325 52568280
Rheumatoid arthritis 124.09 11.64 75 51386 314456 52983149
Contraindicated product administered 116.66 11.64 3 51458 135626 53161979
Neutropenia 113.86 11.64 375 51086 158810 53138795
Death 108.65 11.64 651 50810 356581 52941024
Constipation 102.00 11.64 420 51041 197992 53099613
Malignant neoplasm progression 99.68 11.64 216 51245 71325 53226280
Systemic lupus erythematosus 91.37 11.64 8 51453 125406 53172199
Synovitis 90.53 11.64 3 51458 107890 53189715
Asthenia 87.65 11.64 599 50862 342991 52954614
Toxicity to various agents 87.04 11.64 52 51409 219546 53078059
Arthropathy 86.30 11.64 16 51445 141437 53156168
Blood magnesium decreased 75.87 11.64 74 51387 11740 53285865
Decreased appetite 75.21 11.64 407 51054 214567 53083038
Therapeutic product effect decreased 74.98 11.64 15 51446 125640 53171965
Neutrophil count decreased 73.89 11.64 153 51308 48945 53248660
Joint swelling 73.26 11.64 71 51390 234567 53063038
Full blood count decreased 69.43 11.64 100 51361 23929 53273676
Neuropathy peripheral 66.60 11.64 235 51226 102952 53194653
Heart rate abnormal 64.54 11.64 43 51418 3957 53293648
Hospice care 62.68 11.64 50 51411 6080 53291525
Pleural effusion 61.75 11.64 207 51254 88372 53209233
Akathisia 61.34 11.64 57 51404 8514 53289091
Carbohydrate antigen 125 increased 60.18 11.64 35 51426 2533 53295072
Thrombosis 59.34 11.64 160 51301 60633 53236972
Abdominal pain 58.66 11.64 435 51026 255468 53042137
Neoplasm progression 58.24 11.64 104 51357 29815 53267790
Glossodynia 57.72 11.64 13 51448 100278 53197327
Lymphadenitis 54.99 11.64 34 51427 2751 53294854
Therapeutic product effect incomplete 54.65 11.64 11 51450 91773 53205832
Condition aggravated 53.29 11.64 131 51330 297003 53000602
Clostridium difficile infection 50.54 11.64 94 51367 27799 53269806
Small intestinal obstruction 50.47 11.64 72 51389 17075 53280530
Gangrene 48.20 11.64 39 51422 4838 53292767
Completed suicide 47.71 11.64 38 51423 138163 53159442
Pericarditis 47.19 11.64 4 51457 64402 53233203
Arterial occlusive disease 44.95 11.64 38 51423 5011 53292594
Thrombocytopenia 43.38 11.64 255 51206 138472 53159133
Pancytopenia 43.14 11.64 188 51273 90740 53206865
Neovascularisation 43.14 11.64 18 51443 629 53296976
Injection site erythema 42.51 11.64 11 51450 77238 53220367
Coma 42.24 11.64 5 51456 61778 53235827
Colitis 42.20 11.64 111 51350 41441 53256164
Injection site pain 40.63 11.64 30 51431 113361 53184244
Treatment failure 39.86 11.64 39 51422 128364 53169241
Red blood cell count decreased 39.66 11.64 99 51362 35804 53261801
Maternal exposure during pregnancy 38.99 11.64 56 51405 155583 53142022
Palmar-plantar erythrodysaesthesia syndrome 38.13 11.64 72 51389 21534 53276071
Cytokine release syndrome 38.03 11.64 43 51418 8086 53289519
Failure to thrive 37.96 11.64 40 51421 6952 53290653
General physical health deterioration 37.68 11.64 52 51409 146890 53150715
Pneumonitis 37.13 11.64 88 51373 30800 53266805
Swelling 36.84 11.64 81 51380 191024 53106581
Pain 35.46 11.64 380 51081 588018 52709587
Infusion related reaction 35.37 11.64 60 51401 155897 53141708
Intentional overdose 34.34 11.64 11 51450 67194 53230411
Weight decreased 34.34 11.64 362 51099 234586 53063019
Psoriasis 33.93 11.64 21 51440 87068 53210537
Alopecia areata 33.67 11.64 20 51441 1505 53296100
Blood creatine increased 33.62 11.64 32 51429 4925 53292680
Pneumonia 32.41 11.64 562 50899 406607 52890998
Hair texture abnormal 31.71 11.64 28 51433 3914 53293691
Lower respiratory tract infection 31.41 11.64 25 51436 90956 53206649
Drug intolerance 31.29 11.64 98 51363 205395 53092210
Injection site reaction 30.73 11.64 6 51455 51160 53246445
Hair colour changes 30.62 11.64 24 51437 2845 53294760
Rectal cancer metastatic 30.48 11.64 11 51450 258 53297347
Off label use 30.45 11.64 300 51161 471912 52825693
Psoriatic arthropathy 30.35 11.64 5 51456 48185 53249420
Hepatic enzyme increased 30.06 11.64 47 51414 126148 53171457
Drug hypersensitivity 30.01 11.64 389 51072 264853 53032752
Haemoglobin decreased 28.92 11.64 229 51232 137078 53160527
Anaemia 28.90 11.64 400 51061 276318 53021287
Taste disorder 28.84 11.64 37 51424 7931 53289674
Blood potassium decreased 27.69 11.64 94 51367 40366 53257239
Wound 27.06 11.64 29 51432 91528 53206077
Muscle twitching 26.85 11.64 53 51408 16373 53281232
Hypokalaemia 26.74 11.64 172 51289 96345 53201260
Hypophagia 26.61 11.64 78 51383 30984 53266621
Mucosal inflammation 26.34 11.64 96 51365 42688 53254917
Mobility decreased 26.27 11.64 21 51440 76250 53221355
Sepsis 25.97 11.64 235 51226 146194 53151411
Overdose 24.83 11.64 41 51420 107695 53189910
Dysgeusia 24.49 11.64 94 51367 42837 53254768
Back pain 24.19 11.64 338 51123 233909 53063696
Drug interaction 24.18 11.64 119 51342 219210 53078395
Suicide attempt 24.12 11.64 13 51448 58155 53239450
Asthma 23.72 11.64 43 51418 108929 53188676
Injection site swelling 23.58 11.64 6 51455 42622 53254983
Oral pain 23.58 11.64 68 51393 26769 53270836
Hyponatraemia 23.34 11.64 182 51279 108425 53189180
Gastric disorder 23.26 11.64 73 51388 30092 53267513
Knee arthroplasty 22.25 11.64 3 51458 33566 53264039
Lymphadenopathy 22.03 11.64 81 51380 36174 53261431
Dry skin 21.98 11.64 95 51366 45665 53251940
Cholestasis of pregnancy 21.96 11.64 14 51447 1195 53296410
Exposure during pregnancy 21.60 11.64 56 51405 124804 53172801
Weight increased 21.40 11.64 113 51348 204454 53093151
Red cell distribution width increased 21.22 11.64 34 51427 8926 53288679
Autoimmune nephritis 20.96 11.64 9 51452 338 53297267
Folliculitis 20.63 11.64 3 51458 31706 53265899
C-reactive protein increased 20.62 11.64 21 51440 67865 53229740
Hypoxia 20.49 11.64 107 51354 55573 53242032
Tumour marker increased 20.37 11.64 22 51439 3931 53293674
Pyrexia 20.12 11.64 520 50941 402673 52894932
Musculoskeletal stiffness 20.08 11.64 57 51404 123311 53174294
Discomfort 19.61 11.64 39 51422 95433 53202172
Deep vein thrombosis 19.53 11.64 142 51319 82771 53214834
Skull fracture 19.38 11.64 12 51449 973 53296632
Irritable bowel syndrome 19.22 11.64 9 51452 43623 53253982
Plasma cell myeloma recurrent 19.08 11.64 18 51443 2739 53294866
Madarosis 18.68 11.64 18 51443 2812 53294793
Abortion spontaneous 18.50 11.64 11 51450 46624 53250981
Skin exfoliation 18.17 11.64 76 51385 36007 53261598
Coronary artery disease 17.94 11.64 5 51456 33432 53264173
Laboratory test abnormal 17.85 11.64 58 51403 24351 53273254
Loss of personal independence in daily activities 17.59 11.64 25 51436 69790 53227815
Acquired cystic kidney disease 17.52 11.64 5 51456 53 53297552
Red blood cell sedimentation rate increased 17.47 11.64 3 51458 28054 53269551
Mental status changes 17.39 11.64 80 51381 39491 53258114
Parkinsonism 17.11 11.64 31 51430 8982 53288623
Hypermagnesaemia 16.69 11.64 11 51450 994 53296611
Fibromyalgia 16.65 11.64 11 51450 44064 53253541
Arthralgia 16.48 11.64 312 51149 439471 52858134
Paradoxical drug reaction 16.26 11.64 18 51443 3307 53294298
Injection site pruritus 16.23 11.64 10 51451 41579 53256026
Injection site bruising 16.22 11.64 8 51453 37638 53259967
Morbid thoughts 16.08 11.64 9 51452 605 53297000
Drug reaction with eosinophilia and systemic symptoms 15.67 11.64 6 51455 32794 53264811
Pancreatic carcinoma recurrent 15.58 11.64 5 51456 81 53297524
Nasopharyngitis 15.56 11.64 115 51346 192180 53105425
Clostridium difficile colitis 15.39 11.64 48 51413 19717 53277888
Ill-defined disorder 15.35 11.64 15 51446 49429 53248176
Ovarian cancer recurrent 15.24 11.64 11 51450 1152 53296453
Pulmonary embolism 15.15 11.64 173 51288 114269 53183336
Multiple sclerosis relapse 14.64 11.64 13 51448 44840 53252765
Pregnancy 14.61 11.64 6 51455 31435 53266170
Blood pressure fluctuation 14.60 11.64 8 51453 35462 53262143
Cardiac failure 14.46 11.64 39 51422 85805 53211800
Dyssomnia 14.32 11.64 4 51457 39 53297566
Streptococcal bacteraemia 14.26 11.64 12 51449 1572 53296033
Stomatitis 14.19 11.64 151 51310 98007 53199598
Lymphocyte count decreased 14.06 11.64 59 51402 27993 53269612
Neutropenic sepsis 13.73 11.64 38 51423 14611 53282994
Oesophagitis 13.68 11.64 38 51423 14639 53282966
Chills 13.66 11.64 158 51303 104690 53192915
Dizziness 13.62 11.64 462 50999 371797 52925808
Enteritis 13.37 11.64 25 51436 7421 53290184
Lymph node pain 13.29 11.64 11 51450 1409 53296196
Drug abuse 13.25 11.64 27 51434 65499 53232106
Embolism 13.23 11.64 25 51436 7478 53290127
Intentional self-injury 13.16 11.64 4 51457 25280 53272325
Acute myeloid leukaemia 13.08 11.64 41 51420 16891 53280714
Hypersensitivity 13.05 11.64 135 51326 210530 53087075
Therapeutic response decreased 13.04 11.64 16 51445 47553 53250052
Heart rate decreased 12.94 11.64 10 51451 36937 53260668
Inflammation 12.92 11.64 22 51439 57114 53240491
Diabetes mellitus 12.89 11.64 20 51441 53879 53243726
Abdominal discomfort 12.75 11.64 144 51317 220918 53076687
Plasmacytoma 12.67 11.64 14 51447 2567 53295038
Haematocrit decreased 12.55 11.64 70 51391 37261 53260344
Osteonecrosis 12.47 11.64 5 51456 26570 53271035
Hypomagnesaemia 12.29 11.64 52 51409 24759 53272846
Enterocolitis infectious 12.15 11.64 11 51450 1589 53296016
Intentional product misuse 12.13 11.64 18 51443 49374 53248231
Urinary tract infection 12.11 11.64 310 51151 239593 53058012
Wrong technique in product usage process 11.92 11.64 25 51436 60007 53237598
Product quality issue 11.77 11.64 11 51450 37012 53260593
Ascites 11.73 11.64 72 51389 39663 53257942
Cataract 11.69 11.64 85 51376 49535 53248070

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 319.02 12.59 495 32978 119071 32360982
Nausea 235.05 12.59 793 32680 320056 32159997
Fatigue 177.53 12.59 771 32702 349930 32130123
Disease progression 137.68 12.59 287 33186 86575 32393478
Plasma cell myeloma 125.45 12.59 218 33255 57396 32422657
Dehydration 122.75 12.59 350 33123 128608 32351445
Malignant neoplasm progression 97.02 12.59 235 33238 78261 32401792
Diarrhoea 93.53 12.59 668 32805 364134 32115919
Vomiting 93.16 12.59 483 32990 235074 32244979
Death 92.68 12.59 691 32782 381826 32098227
Pneumonia 87.28 12.59 644 32829 354608 32125445
Decreased appetite 79.60 12.59 352 33121 160461 32319592
Drug interaction 68.80 12.59 74 33399 218111 32261942
White blood cell count decreased 64.92 12.59 224 33249 90974 32389079
Drug abuse 63.68 12.59 5 33468 80238 32399815
Toxicity to various agents 58.79 12.59 58 33415 177983 32302070
Neuropathy peripheral 58.23 12.59 193 33280 76789 32403264
Full blood count decreased 56.09 12.59 78 33395 16932 32463121
Drug ineffective 53.38 12.59 209 33264 383268 32096785
Constipation 53.19 12.59 264 33209 126109 32353944
Platelet count decreased 50.80 12.59 243 33230 114348 32365705
Condition aggravated 48.78 12.59 53 33420 155608 32324445
Neutropenia 43.78 12.59 273 33200 141902 32338151
Completed suicide 41.09 12.59 22 33451 92495 32387558
Small intestinal obstruction 39.38 12.59 60 33413 14136 32465917
Overdose 38.24 12.59 21 33452 87056 32392997
Neutrophil count decreased 38.16 12.59 121 33352 47018 32433035
Failure to thrive 37.74 12.59 45 33428 8390 32471663
Cytokine release syndrome 37.26 12.59 57 33416 13478 32466575
Neoplasm progression 37.14 12.59 70 33403 19588 32460465
Hospice care 37.06 12.59 36 33437 5323 32474730
Rash 36.99 12.59 353 33120 208980 32271073
Back pain 33.38 12.59 212 33261 110841 32369212
Psoriasis 31.26 12.59 5 33468 46118 32433935
Deep vein thrombosis 30.31 12.59 138 33335 63575 32416478
Muscle spasms 30.21 12.59 148 33325 70270 32409783
Asthenia 30.14 12.59 373 33100 235571 32244482
Therapeutic product effect incomplete 29.13 12.59 4 33469 41337 32438716
Intentional overdose 27.11 12.59 5 33468 41596 32438457
Product use in unapproved indication 26.95 12.59 30 33443 87174 32392879
Sepsis 26.13 12.59 264 33209 158570 32321483
Rheumatoid arthritis 25.72 12.59 7 33466 44537 32435516
Thrombosis 25.52 12.59 104 33369 45650 32434403
Adverse drug reaction 25.30 12.59 71 33402 25790 32454263
Bradycardia 25.12 12.59 22 33451 71540 32408513
Rhabdomyolysis 24.45 12.59 20 33453 67245 32412808
Ageusia 24.13 12.59 39 33434 9663 32470390
Pulmonary embolism 24.07 12.59 158 33315 83501 32396552
Suicide attempt 24.07 12.59 5 33468 38239 32441814
Coma 24.04 12.59 7 33466 42605 32437448
General physical health deterioration 23.83 12.59 52 33421 115207 32364846
Laboratory test abnormal 23.37 12.59 57 33416 19030 32461023
Cardiac failure 22.78 12.59 37 33436 91636 32388417
Intentional product misuse 22.11 12.59 5 33468 36046 32444007
Spinal cord compression 21.42 12.59 23 33450 3826 32476227
Wrong technique in product usage process 21.23 12.59 5 33468 35054 32444999
Oral pain 20.70 12.59 37 33436 9941 32470112
Coronary artery disease 20.38 12.59 13 33460 49693 32430360
Dysgeusia 20.16 12.59 65 33408 25466 32454587
Off label use 20.14 12.59 210 33263 306110 32173943
Hyponatraemia 19.80 12.59 138 33335 74375 32405678
Injection site pain 19.46 12.59 5 33468 33053 32447000
C-reactive protein increased 19.15 12.59 13 33460 48089 32431964
Drug reaction with eosinophilia and systemic symptoms 18.95 12.59 5 33468 32480 32447573
Hiccups 18.39 12.59 35 33438 9860 32470193
Weight decreased 17.85 12.59 253 33220 164565 32315488
Hypophagia 16.75 12.59 58 33415 23565 32456488
Mental status changes 16.73 12.59 81 33392 38256 32441797
Treatment failure 16.39 12.59 10 33463 39153 32440900
Diaphragmatic rupture 16.37 12.59 4 33469 20 32480033
Plasma cell myeloma recurrent 16.23 12.59 20 33453 3857 32476196
Bacteraemia 15.88 12.59 47 33426 17586 32462467
Pleural effusion 15.82 12.59 137 33336 78855 32401198
Immune effector cell-associated neurotoxicity syndrome 15.74 12.59 13 33460 1555 32478498
Bacillus bacteraemia 15.37 12.59 5 33468 79 32479974
Foetal exposure during pregnancy 15.35 12.59 12 33461 41289 32438764
Oesophagitis 15.08 12.59 38 33435 12943 32467110
Inappropriate schedule of product administration 15.01 12.59 15 33458 45810 32434243
Asthma 14.92 12.59 14 33459 44051 32436002
Clostridium difficile infection 14.68 12.59 46 33427 17750 32462303
Mixed dementia 14.62 12.59 7 33466 318 32479735
Inferior vena caval occlusion 14.45 12.59 4 33469 35 32480018
Dystonia 14.39 12.59 33 33440 10590 32469463
Tooth disorder 14.36 12.59 32 33441 10075 32469978
Cholestasis 14.26 12.59 5 33468 27028 32453025
Temperature intolerance 14.13 12.59 17 33456 3198 32476855
Hypoxia 14.11 12.59 97 33376 52035 32428018
Wrist deformity 14.07 12.59 7 33466 346 32479707
Haematochezia 13.82 12.59 12 33461 39196 32440857
Enterocolitis infectious 13.75 12.59 11 33462 1257 32478796
Seizure 13.48 12.59 58 33415 103796 32376257
Mucosal inflammation 13.43 12.59 69 33404 33365 32446688
Pneumonitis 13.39 12.59 64 33409 30070 32449983
Myocardial infarction 12.99 12.59 76 33397 125600 32354453
Drug dependence 12.99 12.59 4 33469 23480 32456573
Electrocardiogram QT prolonged 12.95 12.59 13 33460 39628 32440425
Cholangiocarcinoma 12.94 12.59 10 33463 1087 32478966
Anaemia 12.85 12.59 311 33162 223313 32256740
Meconium abnormal 12.82 12.59 3 33470 12 32480041
Pancytopenia 12.81 12.59 147 33326 91088 32388965
Oral candidiasis 12.73 12.59 34 33439 11993 32468060
Respiratory arrest 12.64 12.59 7 33466 28901 32451152

Pharmacologic Action:

SourceCodeDescription
ATC N05AB04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37890 alpha-adrenoceptor antagonists
CHEBI has role CHEBI:48561 dopamine blocker
CHEBI has role CHEBI:48873 Anticholinergika
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:65190 typical antipsychotic drug
CHEBI has role CHEBI:76779 prolyl oligopeptidase (EC 3.4.21.26) inhibitor
CHEBI has role CHEBI:131787 D2 receptor antagonist
FDA EPC N0000175746 Phenothiazine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Schizophrenia indication 58214004 DOID:5419
Nonpsychotic Anxiety indication
Prolonged-Severe Nausea and Vomiting indication
Migraine off-label use 37796009 DOID:6364
Chemotherapy-induced nausea and vomiting off-label use 236084000
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Severe chronic ulcerative colitis contraindication 14311001
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Toxic megacolon contraindication 28536002 DOID:1770
Orthostatic hypotension contraindication 28651003
Atony of colon contraindication 29479008
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Ulcerative colitis contraindication 64766004 DOID:8577
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Extrapyramidal disease contraindication 76349003
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Hyperglycemia contraindication 80394007 DOID:4195
Hiatal hernia contraindication 84089009 DOID:12642
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Gastrointestinal obstruction contraindication 126765001
Acute disease of cardiovascular system contraindication 128487001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Angle-closure glaucoma contraindication 392291006 DOID:13550
Visual impairment contraindication 397540003
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 4.74 Basic
pKa3 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.76 WOMBAT-PK CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.61 WOMBAT-PK IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 7.20 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.64 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.82 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.21 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.40 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.23 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 7.82 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.19 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.91 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.91 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Ki 7.62 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 8.32 DRUG MATRIX
Histamine H1 receptor GPCR Ki 7.72 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 6.61 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.96 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.49 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.72 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.80 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.92 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.86 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.52 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 7.17 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.89 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.70 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.25 DRUG MATRIX
Solute carrier family 22 member 1 Transporter IC50 4.30 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.11 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 7.31 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.92 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.38 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 7.49 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.02 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 6.71 DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.77 CHEMBL

External reference:

IDSource
4018001 VUID
N0000146346 NUI
D00479 KEGG_DRUG
84-02-6 SECONDARY_CAS_RN
4017999 VANDF
4018000 VANDF
4018001 VANDF
C0033229 UMLSCUI
CHEBI:8435 CHEBI
P77 PDB_CHEM_ID
CHEMBL728 ChEMBL_ID
CHEMBL1200587 ChEMBL_ID
CHEMBL1314751 ChEMBL_ID
DB00433 DRUGBANK_ID
CHEMBL1201154 ChEMBL_ID
D011346 MESH_DESCRIPTOR_UI
4917 PUBCHEM_CID
7279 IUPHAR_LIGAND_ID
699 INN_ID
YHP6YLT61T UNII
235739 RXNORM
2073 MMSL
5361 MMSL
5362 MMSL
5363 MMSL
6416 MMSL
6417 MMSL
d00355 MMSL
001478 NDDF
001479 NDDF
001480 NDDF
003466 NDDF
22827004 SNOMEDCT_US
372853006 SNOMEDCT_US
3823007 SNOMEDCT_US
395843006 SNOMEDCT_US
79129001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5105 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5110 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0440-8190 TABLET 5 mg ORAL ANDA 12 sections
Compro HUMAN PRESCRIPTION DRUG LABEL 1 0574-7226 SUPPOSITORY 25 mg RECTAL ANDA 19 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6135 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
Prochlorperazine HUMAN PRESCRIPTION DRUG LABEL 1 0713-0135 SUPPOSITORY 25 mg RECTAL ANDA 13 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0351 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5020 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5021 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-281 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-511 TABLET 5 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 14789-700 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
PROCHLORPERAZINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-327 TABLET 10 mg ORAL ANDA 10 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-571 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-572 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 23155-294 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-497 INJECTION 5 mg INTRAMUSCULAR ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 23155-523 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 25021-790 INJECTION 5 mg INTRAVENOUS ANDA 18 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 33261-141 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 33261-550 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-728 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-729 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine maleate HUMAN PRESCRIPTION DRUG LABEL 1 42708-103 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 43063-353 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 43063-742 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 43066-090 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0109 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0110 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Prochlorperazine HUMAN PRESCRIPTION DRUG LABEL 1 50090-0636 SUPPOSITORY 25 mg RECTAL ANDA 13 sections